A MRSA mystery: how PBP4 and cyclic-di-AMP join forces against β-lactam antibiotics.

The high-level resistance to next-generation β-lactams frequently found in isolates lacking , which encodes the transpeptidase PBP2a traditionally associated with methicillin-resistant (MRSA), has remained incompletely understood for decades. A new study by Lai et al. found that the co-occurrence of mutations in and , which respectively cause increased PBP4-mediated cell wall crosslinking and elevated cyclic-di-AMP levels, produces synergistic β-lactam resistance rivaling that of PBP2a-producing MRSA (L.-Y. Lai, N. Satishkumar, S. Cardozo, V. Hemmadi, et al., mBio 15:e02889-23. 2024, https://doi.org/10.1128/mbio.02889-23). The combined mutations are sufficient to explain the high-level β-lactam resistance of some lacking strains, but the mechanism of synergy remains elusive and an avenue for further research. Importantly, the authors establish that co-occurrence of these mutations leads to antibiotic therapy failure in a infection model. These results underscore the need to consider this unique and novel β-lactam resistance mechanism during the clinical diagnosis of MRSA, rather than relying on as a diagnostic.